

CONTENTS

RATIFICATION PAGE	ii
PLAGIARISM STATEMENT	iii
PREFACE	iv
LIST OF FIGURES	viii
LIST OF TABLES	xi
LIST OF APPENDICES	xiii
ABBREVIATIONS	xiv
LIST OF PUBLICATIONS AND CONFERENCE	xvi
ABSTRACT	xvi
INTISARI	xvii
CHAPTER I INTRODUCTION	1
I.1 Background	1
I.2 Research Question	12
I.3 Research Novelty	13
I.3.1 Previous reported research	13
I.3.2 Novelty of current research	15
I.4 Research Objectives	17
I.5 Research Benefits	18
CHAPTER II LITERATURE REVIEW AND HYPOTHESIS FORMULATION	19
II.1 Literature Review	19
II.1.1 Chalcone and pyrazoline	19
II.1.2 Bioisosterism and bioactivity of the thiophene moiety	22
II.1.3 <i>In silico</i> structure-based drug design (SBDD)	25
II.1.4 Targeting protein strategy in anticancer agent development	30
II.1.5 In vitro drug cytotoxicity	33
II.1.6 Immunocytochemistry (ICC) and protein expression	34
II.2 Hypothesis Formulation	35
II.2.1 Hypothesis I	35
II.2.2 Hypothesis II	37
II.2.3 Hypothesis III	38
II.2.4 Hypothesis IV	39
II.2.5 Hypothesis V	40
II.2.6 Hypothesis VI	41
II.2.7 Research Plan	43
CHAPTER III RESEARCH METHOD	45
III.1 Material and Equipment	45
III.1.1 Materials	45
III.1.2 Equipments	46
III.2 Procedure	47
III.2.1 Molecular docking study	47
III.2.3 Molecular dynamics (MD) simulation	49
III.2.4 Synthesis of chlorothiophene-based chalcone and pyrazoline derivatives	51
III.2.5 In vitro cytotoxicity assay	53
III.2.6 Immunocytochemistry test	54
CHAPTER IV RESULT AND DISCUSSION	56
IV.1 Molecular docking of proposed pyrazoline	56
IV.1.1 Geometry optimization	56

IV.1.2 Docking validation (Redocking)	57
IV.1.3 Binding affinity and interaction result to EGFR and COX-2 protein	59
IV.2 MD simulation	69
IV.2.1 MD simulation of P25 with EGFR and COX-2	70
IV.2.2 MD simulation of P25 with MDM2 and Bcl-2	76
IV.3 Synthesis	82
IV.3.1 Synthesis plan	82
IV.3.2 Synthesis of chlorothiophene-based chalcones	84
IV.3.3 Synthesis of chlorothiophene-based pyrazolines	95
IV.4 Anticancer evaluation	104
IV.4.1 Cytotoxicity screening of chlorothiophene-based chalcones	105
IV.4.2 Cytotoxicity screening of pyrazoline chlorothiophene-based pyrazoline	107
IV.5 Protein expression study	110
IV.5.1 Influence of P25 on the expression of H-Ras protein	111
IV.5.2 Influence of P25 on the expression of p53 protein	113
IV.5.3 Influence of P25 to the expression of Bcl-2 protein	114
IV.5.4 Anticancer mechanism summary of chlorothiophene-based pyrazoline	114
CHAPTER V CONCLUSIONS AND RECOMMENDATIONS	116
V.1 Conclusion	116
V.1 Recommendations	117
REFERENCES	118
APPENDICES	139